DANVERS, Mass., Nov. 22 /PRNewswire-FirstCall/ -- ABIOMED, Inc. announced today that Michael R. Minogue, Chairman, President and Chief Executive Officer, will present at the Lazard Life Sciences Conference on November 30, 2005 at 3:00 p.m. ET. The conference will be held at the New York Palace Hotel in New York City.
A live webcast of the presentation will be made available on the Investor Relations section of the ABIOMED website, http://www.abiomed.com. The webcast will be archived for two weeks.
ABOUT ABIOMED
Based in Danvers, Massachusetts, ABIOMED, Inc. (pronounced “AB'-EE-O-MED”) is a leading developer, manufacturer and marketer of medical products designed to assist or replace the pumping function of the failing heart. ABIOMED currently manufactures and sells the AB5000(TM) Circulatory Support System and the BVS(R) 5000 Biventricular Support System for the temporary support of all patients with failing but potentially recoverable hearts. In Europe, ABIOMED offers the Impella(R) Recover(TM) minimally invasive cardiovascular support systems under CE Mark approval. The Company’s AbioCor(R) Implantable Replacement Heart was the subject of an initial clinical trial under an Investigational Device Exemption from the United States Food and Drug Administration. The AbioCor has not been approved for commercial distribution, and is not available for use or sale outside of the initial clinical trial. For additional information please visit: http://www.abiomed.com.
Contacts: Liza Heapes Investor Relations Contact: ABIOMED, INC. Rx Communications Group, LLC Media Relations Melody A. Carey 978-646-1668 917-322-2571 mediarelations@abiomed.commcarey@rxir.com FORWARD-LOOKING STATEMENTS
This Release contains forward-looking statements, including statements regarding development of ABIOMED’s existing and new products, the Company’s progress toward commercial growth, and future opportunities. The Company’s actual results may differ materially from those anticipated in these forward- looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, anticipated future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, future capital needs and uncertainty of additional financing and other risks and challenges detailed in the Company’s filings with the Securities and Exchange Commission, including the Annual Report filed on Form 10-K. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this Release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this Release or to reflect the occurrence of unanticipated events.
ABIOMED, Inc.
CONTACT: Media Relations: Liza Heapes of ABIOMED, INC., +1-978-646-1668,mediarelations@abiomed.com; or Investor Relations Contact: Melody A. Careyof Rx Communications Group, LLC, +1-917-322-2571, mcarey@rxir.com
Web site: http://www.abiomed.com//
